Skip to main content

Table 1 Baseline characteristics of all episodes of uncomplicated malaria treated with study drugs

From: Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children

Characteristic Treatment Group
  AL (n = 412) DP (n = 425)
Treatment episodes per child, median (range) 2 (1-11) 2 (1-9)
Age at time of treatment in months, mean (SD) 12.5 (3.6) 12.6 (3.8)
   4-10 months, n (%) 104 (25%) 118 (28%)
   >10-12 months, n (%) 111 (27%) 114 (27%)
   >12-15 months, n (%) 85 (21%) 78 (18%)
   >15-22 months, n (%) 112 (27%) 115 (27%)
HIV status, TS use, ARV use   
   HIV-uninfected not taking TS, n (%) 248 (60%) 271 (64%)
   HIV-uninfected taking TS, n (%) 115 (28%) 121 (28%)
   HIV-infected only taking TS, n (%) 8 (1.9%) 8 (1.9%)
   HIV-infected taking TS and ARVs, n (%) 41 (10%) 25 (5.9%)
Duration since last study drug treatment   
   17 - 28 days, n (%) 76 (18%) 18 (4.2%)
   28 - 63 days, n (%) 146 (35%) 192 (45%)
   >63 days or no prior treatment, n (%) 190 (46%) 215 (51%)
\